The Effect of Caffeine on Ischemic Preconditioning
Information source: Radboud University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Caffeine; Ischemic Preconditioning; Ischemia-Reperfusion Injury
Intervention: caffeine (Drug); Technetium-TC99m-labeled Annexin A5 (Drug); ten minutes forearm ischemia (Procedure); ischemic forearm exercise (Procedure)
Sponsored by: Radboud University
Official(s) and/or principal investigator(s):
Gerard Rongen, MD, Phd, Principal Investigator, Affiliation: Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology
Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia
render the (myocardial) muscle more resistant to a subsequent more prolonged period of
ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor
stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor
antagonist already at concentrations reached after regular coffee consumption, we aimed to
assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated
model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle.
24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or
saline before a protocol for IP.
Official title: Caffeine Reduces Acute Ischemic Preconditioning
Study design: Randomized, Double-Blind, Placebo Control, Parallel Assignment
Primary outcome: Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.
Minimum age: 18 Years.
Maximum age: 50 Years.
- healthy male volunteers
Locations and Contacts
Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology, Nijmegen, Gelderland 6500 HB, Netherlands
Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.
Starting date: September 2003
Ending date: January 2006
Last updated: November 28, 2006